-
1
Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg
Published 2023-12-01“…In recent years, real-world studies have become increasingly important to confirm and solidify the clinical potential of novel anti-myeloma therapies.Methods This article describes the real-world experience with isatuximab-based therapy in a selection of four RRMM patients treated with an isatuximab-based treatment regimen in the Grand Duchy of Luxembourg.Results Three of the four cases described in this article consist of heavily pretreated patients who were previously exposed to daratumumab-based therapy. …”
Get full text
Article -
2
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL
Published 2023-09-01“…Results: The study enrolled 152 patients (125 prospective, 27 retrospective) at 15 hospitals in Belgium and Luxembourg. Minimum potential follow-up at time of analysis was 11.4 months. …”
Get full text
Article -
3
-
4
-
5
CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6
Published 2021-03-01Get full text
Article -
6
-
7
-
8
-
9
-
10
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
Published 2021-03-01Get full text
Article -
11
-
12
-
13
Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection
Published 2020-06-01Get full text
Article